Interpace Diagnostics to Present at the 6th Annual Liolios Gateway Conference on September 6, 2017
PARSIPPANY, N.J., Aug. 31, 2017 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) will present at the 6th Annual Gateway investor conference, to be held on September 6-7, 2017 at the Four Seasons Hotel San Francisco. Interpace management is scheduled to present on Wednesday, September 6 at 9:00 a.m. Pacific time, with one-on-one meetings held throughout the conference.
The presentation will be webcast live and available for replay in the Investor Relations section of Interpace’s website at www.interpacedx.com or on the Gateway Conference website at www.gateway-conference.com/presenters. To receive additional information, request an invitation or to schedule a one-on-one meeting, please email email@example.com.
About the Gateway Conference
The 6th Annual Gateway Conference is an invite-only conference presented by Liolios, which brings together the most compelling companies with the nation’s top institutional investors and analysts. This year’s event features more than 100 companies from a number of growth industries, including technology, business and financial services, consumer, digital media, clean technology and life sciences. The format has been designed to give attendees direct access to senior management via company presentations, Q&A sessions and one-on-one meetings. For more information, visit www.gateway-conference.com or www.liolios.com.
About Interpace Diagnostics Group, Inc.
Interpace Diagnostics is a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for better patient diagnosis and management. The Company currently has three commercialized molecular tests; PancraGEN® for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGenX®, for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay and ThyraMIR®, for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay. Interpace Diagnostics' mission is to provide personalized medicine through molecular diagnostics and innovation to advance patient care based on rigorous science.
CONTACTS: Interpace Diagnostics Group, Inc. Investor Relations: Paul Kuntz – RedChip firstname.lastname@example.org
Released August 31, 2017